While germline MAEA KO causes myeloproliferative disease in mice96, it is possible that CTLH inhibition in combination with low-dose FDA-approved PI3K inhibitors such alpelisib may not have this effect. The gene discussed is MAEA; the disease is myeloproliferative disorder.